Immune related adverse events across cancer types: Incidence, risk factors and survival

被引：0
|
作者：
Owen, D. H. [1 ]
Burkart, J. [1 ]
Patel, S. [1 ]
Wei, L. [2 ]
Tinoco, G. [1 ]
Liebner, D. [1 ]
He, K. [1 ]
Shields, P. G. [1 ]
Bertino, E. M. [1 ]
Presley, C. J. [1 ]
Johns, A. [1 ]
Folefac, E. [1 ]
Olencki, T. [1 ]
Carbone, D. P. [1 ]
Verschraegen, C. [1 ]
Otterson, G. A. [1 ]
Kendra, K. L. [1 ]
机构：
[1] Ohio State Univ, Dept Internal Med, Div Med Oncol, James Canc Hosp, Columbus, OH 43210 USA
[2] Ohio State Univ, Ctr Biostat, James Canc Hosp, Columbus, OH 43210 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1772P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Identification of risk factors for gastrointestinal immune-related adverse events associated with immune check point inhibitors
    Morikawa, Ryo
    Nitta, Kentaro
    Yasuda, Shuntaro
    Kano, Yoshihito
    Noji, Rika
    Aoyama, Satoru
    Sato, Shingo
    Ikeda, Sadakatsu
    Okamoto, Ryuichi
    Nagata, Masashi
    Mori, Takehiko
    Suenaga, Mitsukuni
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [32] DIFFERENCES IN THYROID IMMUNE-RELATED ADVERSE EVENTS BETWEEN LUNG CANCER TYPES, A RETROSPECTIVE ANALYSIS
    Jiwani, Rahim
    Brody, Heather
    Mao, Yuxuan
    Lee, Elisabeth
    Rehana, Rita
    Cherry, Cynthia
    Bian, Hui
    Namireddy, Praveen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A114 - A114
  • [33] Immune related adverse events: Timing, identification patterns, and impact on survival
    Deviley, Jake Anthony
    Hayashi-Tanner, Yacki
    Krause, Joshua
    Arenz, Andrea
    Frankki, Susan M.
    Marinier, David E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Risk factors for immune mediated adverse events with immune checkpoint inhibitors.
    Pelcovits, Ari
    Mistry, Hetal
    Chudasama, Rani
    Andrea, Sarah
    Khurshid, Humera
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Incidence and factors associated with cutaneous immune-related adverse events to immune check point inhibitors: An ambispective cohort study
    Luangnara, Athitaya
    Kiratikanon, Salin
    Ketpueak, Thanika
    Suksombooncharoen, Thatthan
    Charoentum, Chaiyut
    Chewaskulyong, Busyamas
    Tovanabutra, Napatra
    Chiewchanvit, Siri
    Nochaiwong, Surapon
    Chuamanochan, Mati
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [36] Risk factors for adverse events related to polypectomy in the English Bowel Cancer Screening Programme
    Rutter, Matthew D.
    Nickerson, Claire
    Rees, Colin J.
    Patnick, Julietta
    Blanks, Roger G.
    ENDOSCOPY, 2014, 46 (02) : 90 - 97
  • [37] CUTANEOUS ADVERSE EVENTS OF IMMUNE CHECKPOINT INHIBITOR THERAPY: INCIDENCE AND TYPES OF REACTIVE DERMATOSES
    Le, Thomas
    Kaul, Subuhi
    Wongvibulsin, Shannon
    Cappelli, Laura
    Naidoo, Jarushka
    Semenov, Yevgeniy
    Kwatra, Shawn
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A509 - A510
  • [38] Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses
    Le, Thomas K.
    Kaul, Subuhi
    Cappelli, Laura C.
    Naidoo, Jarushka
    Semenov, Yevgeniy R.
    Kwatra, Shawn G.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1691 - 1695
  • [39] Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer
    Issa, Majd
    Tang, Joy
    Guo, Yizhen
    Coss, Chris
    Mace, Thomas A.
    Bischof, Jason
    Phelps, Mitch
    Presley, Carolyn J.
    Owen, Dwight H.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (08) : 861 - 874
  • [40] Patterns and risk factors of immune-related adverse events in a real-world cohort with lung cancer receiving immunotherapy
    Hu, Xiao
    Gurinovich, Anastasia
    Pan, Stacey
    Salei, Yana
    Lin, Jeffrey
    Parsons, Susan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345